A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Dacarbazine
Immunocytokine
L19IL2
Phase II study
Stage IV melanoma
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
18
04
2019
accepted:
22
08
2019
pubmed:
5
9
2019
medline:
29
10
2019
entrez:
5
9
2019
Statut:
ppublish
Résumé
Engineered cytokine products represent promising agents for the treatment of immunogenic tumors, such as malignant melanoma, in addition to immune checkpoint inhibitors. Here we describe the results of a controlled, randomized phase II clinical trial, aimed at assessing the therapeutic potential of L19IL2, a fully human fusion protein consisting of the L19 antibody specific to the alternatively spliced extra-domain B of fibronectin, fused to human interleukin-2 in advanced metastatic melanoma. In one arm, patients received dacarbazine (DTIC; 1000 mg/m
Identifiants
pubmed: 31482307
doi: 10.1007/s00262-019-02383-z
pii: 10.1007/s00262-019-02383-z
doi:
Substances chimiques
L19-IL2 immunocytokine
0
Recombinant Fusion Proteins
0
Dacarbazine
7GR28W0FJI
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM